李捷,罗建方,范瑞新,丁焕宇,李光,于长江,付明,周成斌,陈纪言,庄建

• 1:广东省心血管病研究所血管病诊疗中心广东省人民医院广东省医学科学院

摘要(Abstract)：

目的总结应用VENUS-A瓣膜行经导管主动脉瓣置入术(TAVI)治疗症状性重度主动脉瓣狭窄(AS)的经验。方法回顾性收集分析在广东省人民医院接受TAVI治疗患者的基线特征、术前评估、介入情况及早、中期临床结局。结果 2016年4月至2017年4月共10例症状性重度AS患者接受TAVI治疗,中位年龄75(65,81)岁,其中男5例(5/10),美国胸外科医师学会(STS)评分为5%(2%,11%);手术成功率10/10,同期行经皮冠状动脉介入治疗患者2例(2/10);中位手术时间190(150,225)min,术后ICU监护时间113(49,231)h,术后住院时间12(6,25)d。术后即刻主动脉瓣跨瓣压差均值下降至10(6,21)mmHg(1 mmHg=0.133 kPa),术后即刻微量瓣周漏2例(2/10),轻度瓣周漏3例(3/10),中度瓣周漏1例(1/10)。术后30 d内,1例(1/10)出现围术期心肌梗死、心室颤动而死亡,1例(1/10)术后第4天无法恢复窦性心律而植入永久起搏器,2例(2/10)出现血管并发症。中位随访时间为3(1,15)个月,1例(1/9)术后6个月出现晕厥,R-R间期最长达7 s,从而植入永久起搏器。9例患者均存活,无卒中、转外科开胸手术、心力衰竭再次入院。结论应用VENUS-A瓣膜进行TAVI治疗症状性重度AS是可行、安全和有效的。

关键词(KeyWords)： 主动脉瓣狭窄;经导管主动脉瓣置入术;VENUS-A瓣膜

Abstract:

Keywords:

基金项目(Foundation): 广东省公益研究与能力建设专项(2014A020215023);; 广州市产学研协同创新重大专项(1561000356)

作者(Author): 李捷,罗建方,范瑞新,丁焕宇,李光,于长江,付明,周成斌,陈纪言,庄建

参考文献(References)：

• [1]Leon MB,Smith CR,Mack M,et al.Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery.N Engl J Med,2010,363(17):1597-1607.
• [2]Iung B,Cachier A,Baron G,et al.Decision-making in elderly patients with severe aortic stenosis:why are so many denied surgery?Eur Heart J,2005,26(24):2714-2720.
• [3]Cribier A,Eltchaninoff H,Bash A,et al.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description.Circulation,2002,106(24):3006-3008.
• [4]Holmes DR Jr,Mack MJ,Kaul S,et al.2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement.J Am Coll Cardiol,2012,59(13):1200-1254.
• [5]Vahanian A,Alfieri O,Andreotti F,et al.Guidelines on the management of valvular heart disease(version 2012):the joint task force on the management of valvular heart disease of the European Society of Cardiology(ESC)and the European Association for CardioThoracic Surgery(EACTS).Eur J Cardiothorac Surg,2012,42(4):S1-S44.
• [6]Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,63(22):e57-e185.
• [7]Nishimura RA,Otto CM,Bonow RO,et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol,2017,70(2):252-289.
• [8]葛均波,周达新,潘文志,等.经皮主动脉瓣植入术一例及其操作要点.中国介入心脏病学杂志,2010,18(5):243-246.
• [9]罗建方,范瑞新,李光,等.应用VENUS-A瓣膜完成经导管主动脉瓣植入术的经验总结.岭南心血管病杂志,2016,22(5):549-553.
• [10]Smith CR,Leon MB,Mack MJ,et al.Transcatheter versus surgical aortic-valve replacement in high-risk patients.N Engl J Med,2011,364(23):2187-2198.
• [11]Mack MJ,Leon MB,Smith CR,et al.5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis(PARTNER 1):a randomised controlled trial.Lancet,2015,385(9986):2477-2484.
• [12]Adams DH,Popma JJ,Reardon MJ,et al.Transcatheter aortic-valve replacement with a self-expanding prosthesis.N Engl J Med,2014,370(19):1790-1798.
• [13]中国医师协会心血管内科医师分会结构性心脏病专业委员,中华医学会心血管病学分会结构性心脏病学组.经导管主动脉瓣置换术中国专家共识.中国介入心脏病学杂志,2015,23(12):661-667.
• [14]Thourani VH,Kodali S,Makkar RR,et al.Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients:a propensity score analysis.Lancet,2016,387(10034):2218-2225.
• [15]Reardon MJ,Van Mieghem NM,Popma JJ,et al.Surgical or transcatheter aortic-valve replacement in intermediate-risk patients.N Engl J Med,2017,376(14):1321-1331.
• [16]Van Mieghem NM,Tchetche D,Chieffo A,et al.Incidence,predictors,and implications of access site complications with transfemoral transcatheter aortic valve implantation.Am J Cardiol,2012,110(9):1361-1367.